Vanda Pharmaceuticals Announces Presentations at SLEEP 2024

Rhea-AI Summary

Vanda Pharmaceuticals has announced its participation in SLEEP 2024, a conference set to take place in Houston, TX from June 1-5, 2024. The company will present four research studies on June 4, 2024, conducted by Dr. Sandra Paulina Smieszek, Head of Genetics. The presentations will cover drug and CRISPR/Cas9 screening of HCN channels, the impact of melanopsin crispants in zebrafish on sleep latency, genetic variants linked to dim light melatonin onset in delayed sleep-wake phase disorder (DSWPD) patients, and genetic variants associated with total sleep time (TST) and latency to persistent sleep (LPS) in insomnia patients based on whole genome sequencing.

Positive

• Vanda Pharmaceuticals is participating in a prominent industry conference, SLEEP 2024.
• Four research studies are being presented, highlighting the company's ongoing research and development efforts.
• The presentations cover cutting-edge topics such as CRISPR/Cas9 screening and genetic variants associated with sleep disorders.
• The research is conducted by a specialized professional, Dr. Sandra Paulina Smieszek, enhancing the credibility of the findings.

Negative

• The press release does not mention any immediate financial benefits or potential revenue from the presented studies.
• There is no information on the potential commercial application or clinical trial phases related to the discussed research.
• The impact of the research on the company's stock performance remains uncertain due to the lack of clear actionable outcomes.

WASHINGTON, May 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2024, to be held in Houston, TX from June 1 through June 5, 2024.

The following will be presented:

June 4, 2024

Presentation Title: "Drug Screening and CRISPR/Cas9 Screening of HCN Channels"
Poster Presentation Session: P-17
Poster Number: 10
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics

Presentation Title: "Melanopsin Crispants in Zebrafish Display Difference in Sleep Latency"
Poster Presentation Session: P-17
Poster Number: 11
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics

Presentation Title: "Genetic Variants Associated with Dim Light Melatonin Onset in a Delayed Sleep-Wake Phase Disorder Cohort"
Poster Presentation Session: P-22
Poster Number: 146
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics

Presentation Title: "Genetic variants associated with TST and LPS in insomnia patients: whole genome sequencing study"
Poster Presentation Session: Late-Breaking Abstracts (LBA); P-31
Poster Number: 451
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics

For more information on SLEEP 2024, please refer to https://www.sleepmeeting.org/

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-presentations-at-sleep-2024-302158424.html

SOURCE Vanda Pharmaceuticals Inc.

FAQ

What is Vanda Pharmaceuticals presenting at SLEEP 2024?

Vanda Pharmaceuticals is presenting four studies on drug and CRISPR/Cas9 screening of HCN channels, melanopsin crispants in zebrafish, genetic variants linked to dim light melatonin onset in DSWPD, and genetic variants associated with TST and LPS in insomnia patients.

When and where is SLEEP 2024 taking place?

SLEEP 2024 will take place in Houston, TX from June 1-5, 2024.

Who is presenting Vanda Pharmaceuticals' research at SLEEP 2024?

Dr. Sandra Paulina Smieszek, Head of Genetics at Vanda Pharmaceuticals, will be presenting the research.

What are the titles of Vanda Pharmaceuticals' presentations at SLEEP 2024?

The titles include 'Drug Screening and CRISPR/Cas9 Screening of HCN Channels', 'Melanopsin Crispants in Zebrafish Display Difference in Sleep Latency', 'Genetic Variants Associated with Dim Light Melatonin Onset in a Delayed Sleep-Wake Phase Disorder Cohort', and 'Genetic variants associated with TST and LPS in insomnia patients: whole genome sequencing study'.

What is the stock symbol for Vanda Pharmaceuticals?

The stock symbol for Vanda Pharmaceuticals is VNDA.